Received Aug 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
HCP reported patient received 1st dose of GARDASIL 9 at 12 years old and did not return for 2nd dose until she was "20 something" years old.; No additional AE/PQC reported.; This spontaneous report was received from a pharmacist and refers to a female patient of unknown age. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, at 12 years old, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (dose, route of administration, vaccination site, lot # and expiration date were not reported) administered for prophylaxis. On an unknown date, when the patient was approximately 20 years old, she vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (dose, route of administration, vaccination site, lot # and expiration date were not reported) administered for prophylaxis (inappropriate schedule of product administration). No other information was provided. No additional adverse event (AE) or product quality complaint (PQC) was reported (no adverse event).